-
A picture to understand Several policies and measures for Shanghai to accelerate the construction of a global biomedical R&D economy and industrialization highland
Time of Update: 2023-01-05
Encourage the physical operation of biomedical R&D centers, introduce and cultivate innovative headquarters, improve the incubation and cultivation mechanism of science and technology enterprises, optimize support policies such as R&D and production, strengthen the guidance of fiscal funds to social capital, further increase the total economic contribution of Shanghai biomedical R&D, and build a global biomedical R&D economy and industrialization highland.
-
Puli's new improved drug, Memantine Hydrochloride Granules, is in full swing
Time of Update: 2022-08-10
Figure 1: 2021 Memantine Sales Percentage in Various End Markets Source: Mi intranet database The terminals of public medical institutions in China are the main battlefield of Memantine.
-
The field of oncology has become a battleground for pharmaceutical companies. What are the future trends
Time of Update: 2022-03-07
First, Chinese oncology drugs are still dominated by traditional chemical drugs, but from the perspective of the overall research and development trend, targeted drug therapy and immunotherapy are developing rapidly, and the industry expects that they will become an important force in the field of anti-tumor in the future .
-
Ambroxol hydrochloride oral solution, a subsidiary of Hengrui Medicine, was approved for marketing
Time of Update: 2022-01-25
The approved drug Ambroxol Hydrochloride Oral Liquid can increase the secretion of mucous glands in the respiratory tract and reduce the secretion of mucous glands, thereby reducing the viscosity of sputum, and at the same time promoting the secretion of pulmonary surfactant, increasing the movement of bronchial cilia to make sputum easier to cough up, suitable for For acute and chronic bronchitis caused by thick sputum, difficult expectoration .
-
Boshengji Pharmaceutical's CD7-targeted CAR-T cell injection obtained the U.S. FDA orphan drug designation
Time of Update: 2021-12-01
(hereinafter referred to as "Boshengji") announced its development of CD7-targeted chimeric antigen receptor (CAR)-T cell injection (PA3-17 injection) received US food and drug Administration Administration ( the FDA ) granted orphan drug qualification (orphan drug Designation, ODD), for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia / lymphoma (T-cell acute lymphoblastic leukemia / lymphoma (T-ALL/LBL)) .
-
Corium Donepezil transdermal patch Adlarity new drug application is expected to be approved next year
Time of Update: 2021-10-21
On October 12, 2021, Corium announced that the US FDA has set the new drug application (NDA) PDUFA target date for its donepezil (donepezil) transdermal patch Adlarity to March 11, 2022 for the treatment of mild/medium/ Patients with dementia caused by severe Alzheimer's disease .
-
19 provinces including Hubei, Hebei and other provinces began to purchase Chinese patent medicines in volume, and the tide of price cuts struck again
Time of Update: 2021-09-28
Recently, Hubei Province Pharmaceutical Price and Bidding Procurement Management issued the "Announcement of Centralized Procurement of Chinese Patent Medicine Interprovincial Alliance (No.
It is understood that, in addition to the 19 provinces announced by Hubei Province to purchase Chinese patent medicines in bulk, many places have recently started the centralized procurement of Chinese patent medicines .
-
Winning at the starting point: CDE has focused on the application of biomarkers in the clinical development of anti-tumor drugs
Time of Update: 2021-06-11
June 2021 On July 2, the official website of the Center for Drug Evaluation of the National Medical Products Administration issued the "Technical Guidelines for the Application of Biomarkers in the Clinical Development of Anti-tumor Drugs (Draft for Comment)".
-
Out-of-hospital market breaks out, prescription circulation rules are released, injections are excluded
Time of Update: 2021-06-04
On May 24, the Hunan Provincial Health Commission, together with the Hunan Provincial Administration of Traditional Chinese Medicine and the Hunan Provincial Drug Administration, issued the "Notice o
-
CStone's KIT/PDGFRA mutant kinase inhibitor avatinib was approved in China
Time of Update: 2021-04-24
Today, China’s National Food and Drug Administration (NMPA) drug approval certificate pending information shows that the KIT and PDGFRA mutant kinase inhibitor avapritinib (previously used Chinese name: apotinib) declared by CStone Pharmaceuticals is already available.
-
Tylenol Microlab TNM002 monoclonal antibody successfully obtained IND approval from the US FDA
Time of Update: 2021-03-27
, referred to as “Tinomab” and “Trinomab”) announced its self-developed recombinant anti-tetanus toxin monoclonal antibody drug TNM002 Its clinical trial application (IND) was officially approved by the U.
TNM002 is a natural and fully human monoclonal antibody drug developed by Trinomab using its HitmAb® technology platform with independent intellectual property rights.
-
Nature Sub-journal: 2020 Biopharmaceutical Market of the Year
Time of Update: 2021-01-26
's top 10 deals for total M.A. deals in 2020 (Pharmaceutical Mingkang Content Team Translation, Source: References) Gilead continues to expand its corporate reach in the oncology sector, acquiring Forty Seven for $4.9 billion and Immunomedics for $21 billion, respectively.
-
Publicity of information on provincial food safety supervision and sampling by jilin Food and Drug Administration (No. 30 of 2018
Time of Update: 2021-01-08
Recently, Jilin Food and Drug Administration sampling food and beverage food, bee products, pastries, cooking oil, oil and its products, beverages, grain processing products, biscuits, tea and related products, fried food and nut products, egg products, starch and starch products, canned goods, alcohol, sugar, edible agricultural products, vegetable products, potato and puffed food, fruit products, confectionery products, condiments and other 20 batches of food samples, 3 batches of samples.
-
Effectively strengthen the quality control of the heart stent and effectively strengthen the quality control of the heart stent
Time of Update: 2020-11-29
The State Drug Administration recently issued "on strengthening the national centralized belt volume procurement in the selection of crown stent quality supervision notice", requiring all regions to strengthen supervision, to ensure centralized belt procurement crown stent quality and safety, enterprises should establish and improve the crown vein support product traceability system, and effectively do a good job in product recall, tracking and tracing related work.
-
The Central Commission for Discipline Inspection again: the credit evaluation system makes the briber pay a huge price
Time of Update: 2020-10-31
Pharmaceutical enterprises will face written warnings, relying on centralized procurement platform to the purchaser to prompt risk information, limit or suspend the relevant drugs or medical supplies hanging network, limit or suspend the procurement of related drugs or medical supplies, disclosure of disin facts and other disposal measures, misinreination involving the number of provinces to meet the prescribed conditions, will also be initiated by the State Health Insurance Administration pharmaceutical prices and tender procurement guidance center national joint disposal.
